Verve Therapeutics, Inc.
NASDAQ:VERV
5.46 (USD) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 11.758 | 1.941 | 0 | 0 | 0 |
| Cost of Revenue
| 5.455 | 6.711 | 3.377 | 1.328 | 0.106 |
| Gross Profit
| 6.303 | -4.77 | -3.377 | -1.328 | -0.106 |
| Gross Profit Ratio
| 0.536 | -2.457 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 184.946 | 130.095 | 68.202 | 35.371 | 11.144 |
| General & Administrative Expenses
| 49.936 | 37.533 | 18.865 | 5.256 | 2.498 |
| Selling & Marketing Expenses
| -5.455 | 0 | 0 | 0 | 0 |
| SG&A
| 44.481 | 37.533 | 18.865 | 5.256 | 2.498 |
| Other Expenses
| 0.165 | 1.486 | -33.389 | -5.239 | -5.933 |
| Operating Expenses
| 229.427 | 167.628 | 87.067 | 40.627 | 13.642 |
| Operating Income
| -223.124 | -165.687 | -87.067 | -40.627 | -13.642 |
| Operating Income Ratio
| -18.976 | -85.362 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 23.331 | 8.353 | -33.247 | -5.077 | -5.655 |
| Income Before Tax
| -199.793 | -157.334 | -120.314 | -45.704 | -19.297 |
| Income Before Tax Ratio
| -16.992 | -81.058 | 0 | 0 | 0 |
| Income Tax Expense
| 0.275 | 0.053 | -1.677 | -0.162 | -0.278 |
| Net Income
| -200.068 | -157.387 | -118.637 | -45.542 | -19.019 |
| Net Income Ratio
| -17.015 | -81.086 | 0 | 0 | 0 |
| EPS
| -3.12 | -2.91 | -2.45 | -0.94 | -0.39 |
| EPS Diluted
| -3.12 | -2.91 | -2.45 | -0.94 | -0.39 |
| EBITDA
| -217.669 | -162.883 | -87.067 | -39.299 | -13.536 |
| EBITDA Ratio
| -18.512 | -83.917 | 0 | 0 | 0 |